



1 fn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO. 084335-0182

Applicant: Takao ISOGAI et al.
Title: FULL-LENGTH cDNA
Appl. No.: 10/777,288
Filing Date: 02/13/2004
Examiner: Unassigned
Art Unit: 1653

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding European application. A copy of the European Search Report is attached setting forth the portion of each document considered relevant by the examiner. The absence of a translation does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

September 6, 2005

Date

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: (202) 672-5569


Facsimile: (202) 672-5399

Respectfully submitted,

Michael M. Maebius
Reg No. 34,717

for
Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/777,288
		Filing Date	02/13/2004
		First Named Inventor	Takao ISOGL et al.
		Group Art Unit	1653
		Examiner Name	Unassigned
Sheet 1 of 1	Attorney Docket Number	084335-0182	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	EP	1 195 434	A	Taisho Pharmaceutical Co.	04/10/2002		
	A2	WO	02/068652	A	Curagen Corporation	09/06/2002		
	A3	WO	2004/016225	A	Genentech, Inc.	02/26/2004		
	A4	WO	2004/024760	A	Takeda Chemical Ind. Ltd.	03/25/2004		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A5	Database EMBL, December 13, 2001, STRAUSBERG et al., "Homo Sapiens Solute Carrier Family 10 (Sodium/Bile Acid Cotransporter Family), Member 4 mRNA (cDNA Clone MGC: 29802 Image 4897519), Complete CDS," XP-002332592.	
	A6	DATABASE EMBL, December 1, 2001, STRAUSBERG et al., "Solute Carrier Family 10 (Sodium/Bile Acid Cotransporter Family), Member 4," XP-002332593.	
	A7	DATABASE EMBL, December 18, 2003, "Sequence 113 From Patent WO 02/068652," XP-002332594.	
	A8	DATABASE EPO PROTEINS, December 18, 2003, "Sequence 114 From Patent WO 02/068652," XP-002332595.	
	A9	DATABASE EMBL, September 9, 2003, YAMAMOTO, "Homo Sapiens cDNA FLJ44578 Fis, Clone 3NB692004045, Weakly Similar to Sodium/bile Acid Cotransporter," XP-002332596.	
	A10	DATABASE GENESEQ, May 20, 2004, "Human Tumour-Associated Antigenic Target (TAT) cDNA Sequence #69," XP-002332597.	
	A11	DATABASE GENESEQ, May 20, 2004, "Human Tumour-Associated Antigenic Target (TAT) Polypeptide #65," XP-002332598.	
	A12	DATABASE GENESEQ, June 17, 2004, "Human TCH162 cDNA, Seq. Id 15," XP-002332599.	
	A13	DATABASE GENESEQ, September 16, 2004, "Novel Protein and its DNA," XP-002332600.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.